Regeneron Pharmaceuticals, Inc.
EYLEA HD
wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on EYLEA HD for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“EYLEA HD approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)”